BR112015001521A2 - previsão de resposta ao tratamento para inibidor jak/stat - Google Patents
previsão de resposta ao tratamento para inibidor jak/statInfo
- Publication number
- BR112015001521A2 BR112015001521A2 BR112015001521A BR112015001521A BR112015001521A2 BR 112015001521 A2 BR112015001521 A2 BR 112015001521A2 BR 112015001521 A BR112015001521 A BR 112015001521A BR 112015001521 A BR112015001521 A BR 112015001521A BR 112015001521 A2 BR112015001521 A2 BR 112015001521A2
- Authority
- BR
- Brazil
- Prior art keywords
- jak
- stat inhibitor
- prediction
- treatment response
- stat
- Prior art date
Links
- 101100366892 Anopheles gambiae Stat gene Proteins 0.000 title abstract 4
- 101100366894 Drosophila melanogaster Stat92E gene Proteins 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261676484P | 2012-07-27 | 2012-07-27 | |
| US201361769271P | 2013-02-26 | 2013-02-26 | |
| US201361829327P | 2013-05-31 | 2013-05-31 | |
| PCT/US2013/051824 WO2014018632A1 (en) | 2012-07-27 | 2013-07-24 | Prediction of treatment response to jak/stat inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015001521A2 true BR112015001521A2 (pt) | 2017-11-07 |
Family
ID=48906529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015001521A BR112015001521A2 (pt) | 2012-07-27 | 2013-07-24 | previsão de resposta ao tratamento para inibidor jak/stat |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20150299796A1 (https=) |
| EP (1) | EP2877596A1 (https=) |
| JP (1) | JP2015526074A (https=) |
| KR (1) | KR20150038241A (https=) |
| CN (1) | CN104508149A (https=) |
| AU (2) | AU2013295855A1 (https=) |
| BR (1) | BR112015001521A2 (https=) |
| CA (1) | CA2880198A1 (https=) |
| CL (1) | CL2015000192A1 (https=) |
| HK (1) | HK1205198A1 (https=) |
| IL (1) | IL236897A0 (https=) |
| MX (1) | MX2015001269A (https=) |
| PH (1) | PH12015500169A1 (https=) |
| RU (1) | RU2015106714A (https=) |
| SG (1) | SG11201500261VA (https=) |
| TN (1) | TN2015000019A1 (https=) |
| TW (1) | TW201409030A (https=) |
| WO (1) | WO2014018632A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| EP3099717B1 (en) | 2014-01-31 | 2019-03-27 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
| US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| AU2015327868A1 (en) | 2014-10-03 | 2017-04-20 | Novartis Ag | Combination therapies |
| HK1248603A1 (zh) | 2015-03-10 | 2018-10-19 | Aduro Biotech, Inc. | 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法 |
| DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| CN106544414A (zh) * | 2016-10-09 | 2017-03-29 | 广州泰诺迪生物科技有限公司 | 一种检测肺癌脑转移样本中stat3和lck的方法 |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| CN107137701B (zh) * | 2017-05-07 | 2020-07-14 | 山东兴瑞生物科技有限公司 | 一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
| US20060194275A1 (en) * | 2001-04-13 | 2006-08-31 | Incyte Corporation | Transporter and ion channels |
| WO2010048123A2 (en) * | 2008-10-20 | 2010-04-29 | Eckhardt S Gail | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| CN102459258B (zh) * | 2009-06-05 | 2015-11-25 | 赛福伦公司 | 1,2,4-三唑并[1,5a]吡啶衍生物的制备和用途 |
| WO2012071612A1 (en) * | 2010-12-03 | 2012-06-07 | Ym Biosciences Australia Pty Ltd | Treatment of jak2-mediated conditions |
-
2013
- 2013-07-24 BR BR112015001521A patent/BR112015001521A2/pt not_active IP Right Cessation
- 2013-07-24 SG SG11201500261VA patent/SG11201500261VA/en unknown
- 2013-07-24 WO PCT/US2013/051824 patent/WO2014018632A1/en not_active Ceased
- 2013-07-24 RU RU2015106714A patent/RU2015106714A/ru not_active Application Discontinuation
- 2013-07-24 US US14/417,632 patent/US20150299796A1/en not_active Abandoned
- 2013-07-24 MX MX2015001269A patent/MX2015001269A/es unknown
- 2013-07-24 KR KR20157004583A patent/KR20150038241A/ko not_active Withdrawn
- 2013-07-24 EP EP13742819.9A patent/EP2877596A1/en not_active Withdrawn
- 2013-07-24 JP JP2015524417A patent/JP2015526074A/ja active Pending
- 2013-07-24 AU AU2013295855A patent/AU2013295855A1/en not_active Abandoned
- 2013-07-24 CN CN201380040005.0A patent/CN104508149A/zh active Pending
- 2013-07-24 CA CA2880198A patent/CA2880198A1/en not_active Abandoned
- 2013-07-24 HK HK15105427.5A patent/HK1205198A1/xx unknown
- 2013-07-26 TW TW102126993A patent/TW201409030A/zh unknown
-
2015
- 2015-01-16 TN TNP2015000019A patent/TN2015000019A1/fr unknown
- 2015-01-22 IL IL236897A patent/IL236897A0/en unknown
- 2015-01-26 CL CL2015000192A patent/CL2015000192A1/es unknown
- 2015-01-26 PH PH12015500169A patent/PH12015500169A1/en unknown
-
2017
- 2017-07-14 AU AU2017204894A patent/AU2017204894A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015526074A (ja) | 2015-09-10 |
| RU2015106714A (ru) | 2016-09-20 |
| CL2015000192A1 (es) | 2015-06-26 |
| MX2015001269A (es) | 2015-05-08 |
| IL236897A0 (en) | 2015-03-31 |
| TN2015000019A1 (en) | 2016-06-29 |
| KR20150038241A (ko) | 2015-04-08 |
| US20150299796A1 (en) | 2015-10-22 |
| AU2013295855A1 (en) | 2015-02-12 |
| PH12015500169A1 (en) | 2015-03-16 |
| EP2877596A1 (en) | 2015-06-03 |
| WO2014018632A1 (en) | 2014-01-30 |
| SG11201500261VA (en) | 2015-02-27 |
| CN104508149A (zh) | 2015-04-08 |
| AU2017204894A1 (en) | 2017-08-03 |
| CA2880198A1 (en) | 2014-01-30 |
| TW201409030A (zh) | 2014-03-01 |
| HK1205198A1 (en) | 2015-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015001521A2 (pt) | previsão de resposta ao tratamento para inibidor jak/stat | |
| CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
| BR112015022197A2 (pt) | tratamento de cataplexia | |
| BR112017007072A2 (pt) | compostos de triazolopiridina e métodos para o tratamento de fibrose cística | |
| MX375706B (es) | Compuestos de inhibidor de autotaxina. | |
| BR112016009889A2 (pt) | ?compostos agonistas duplos gip-glp-1 e métodos? | |
| BR112013020798A2 (pt) | terapia de combinação do inibidor mtor /jak | |
| MX365835B (es) | Uso de akkermansia para tratar trastornos metabolicos. | |
| PH12015500587A1 (en) | Combination of regorafenib and acetylsalicylic acid for treating cancer | |
| UY32989A (es) | Coposiciones terapéuticas concentradas de fosfolípidos | |
| CL2016000378A1 (es) | Composiciones y métodos terapéuticos para la regresión acelerada de placa | |
| CL2008001124A1 (es) | Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer. | |
| BR112015009746A2 (pt) | Agente que aumenta atividade de glicocerebrosidase em mamíferos | |
| MX382516B (es) | Composiciones y metodos para absorcion transmucosa. | |
| HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| BR112015005369A2 (pt) | inibidores de usp30 e métodos para sua utilização | |
| BR112014002141A2 (pt) | crizotinib para uso no tratamento de câncer | |
| MX374944B (es) | Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria. | |
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| BR112014020113A8 (pt) | Composições farmacêuticas e método para diminuir a frequência de micção | |
| BR112015019564A2 (pt) | tratamento de esclerose múltipla com laquinimod | |
| EP4385563A3 (en) | Dosage forms and therapeutic uses l-4-chlorokynurenine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2524 DE 21-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |